bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Elevated anti-SARS-CoV-2 antibodies and IL-6, IL-8, MIP-1Œ≤, early predictors of
severe COVID-19.

Helena Codina*1, Irene Vieitez*2, Alicia Gutierrez-Valencia3, Vasso Skouridou4, Cristina
Mart√≠nez5, Luc√≠a Pati√±o1, Mariluz Botero-Gallego4, Mar√≠a Trujillo-Rodr√≠guez3, Ana SernaGallego3, Esperanza Mu√±oz-Muela3, Mar√≠a M. Bobillo1, Alexandre P√©rez1,6, Jorge Julio
Cabrera-Alvar7, Manuel Crespo6, Ciara K. O‚ÄôSullivan4,8, Ezequiel Ruiz-Mateos3 and Eva
Poveda1 on behalf of the Cohort COVID-19 of the Galicia Sur Health Research Institute.

1. Group of Virology and Pathogenesis; Galicia Sur Health Research Institute (IIS Galicia
Sur). SERGAS-UVigo, Vigo, Spain.
2. Rare Diseases & Pediatric Medicine Research Group, Galicia Sur Health Research
Institute (IIS Galicia Sur). SERGAS-Uvigo, Vigo, Spain.
3. Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of
Biomedicine of Seville, IBiS, Virgen del Roc√≠o University Hospital/CSIC/University of
Seville, Seville, Spain.
4. INTERFIBIO Consolidated Research Group, Departament d‚Äô Enginyeria Quimica,
Universitat Rovira i Virgili, Tarragona, Spain.
5. Methodology and Statistics Unit, Galicia Sur Health Research Institute (IIS Galicia
Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain.
6. Infectious Diseases Unit, Department of Internal Medicine, Complexo Hospitalario
Universitario de Vigo, IIS Galicia Sur, SERGAS-UVigo, Vigo, Spain.
7. Microbiology Service, Galicia Sur Health Research Institute (IIS Galicia Sur).
SERGAS-Uvigo, Vigo, Spain.
8. Instituci√≥ Catalana de Recerca i Estudis Avan√ßats, Barcelona, Spain.

*These authors contributed equally to this work

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Corresponding author: Dr. Eva Poveda: eva.poveda.lopez@sergas.es

Members of COHVID-GS (Galicia Sur Health Research Institute): Alejandro Araujo,
Jorge Julio Cabrera, V√≠ctor del Campo, Manuel Crespo, Alberto Fern√°ndez, Beatriz Gil
de Araujo, Carlos G√≥mez, Virginia Leiro, Mar√≠a Rebeca Longueira, Ana L√≥pezDom√≠nguez, Jos√© Ram√≥n Lorenzo, Mar√≠a Marcos, Alexandre P√©rez, Mar√≠a Teresa
P√©rez, Lucia Pati√±o, Sonia P√©rez, Silvia P√©rez-Fern√°ndez, Eva Poveda, Cristina Ramos,
Benito Regueiro, Cristina Retresas, Tania Rivera, Olga Souto, Isabel Taboada, Susana
Teijeira, Mar√≠a Torres, Vanesa Val, Irene Vi√©itez

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

ABSTRACT
Background: Viral and host immune kinetics during acute COVID-19 and after
remission of acute symptoms need better characterization.
Methods: SARS-CoV-2 RNA, anti-SARS-CoV-2 IgA, IgM, and IgG antibodies, and proinflammatory cytokines were measured in sequential samples among hospitalized
COVID-19 patients during acute infection and 6 months following diagnosis.
Results: 24 laboratory-confirmed COVID-19 patients with mild/moderate and severe
COVID-19 were included. Most were males 83%, median age of 61 years. 21% were
admitted to the ICU and 8 of them (33.3%) met criteria for severe COVID-19 disease. A
delay in SARS-CoV-2 levels decline during the first 6 days of follow-up and viral load
persistence until month 3 were related with severe COVID-19, but not viral load levels at
the diagnosis. Higher levels of anti-SARS-CoV-2 IgA, IgM, IgG and the cytokines IL-6,
IL-8 and MIP-1Œ≤ at the diagnosis time were related with severe COVID-19 outcome.
Higher levels of MIP-1Œ≤, IL-1Œ≤, MIP-1ùõº and IFN-ùõæ were observed at month 1/3 during
mild/moderate disease compared to severe COVID-19. IgG persisted at low levels after
6 months of diagnosis.
Conclusions: Higher concentrations of IgA, IgM, and IgG, and IL-6, IL-8 and MIP-1Œ≤ are
identified as early predictors of COVID-19 severity, but not SARS-CoV-2 RNA levels at
diagnosis.
Key Words: SARS-CoV-2, severe COVID-19, anti-SARS-CoV-2 antibodies, cytokines,
viral load

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

INTRODUCTION
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), rapidly spread worldwide becoming a global
public health emergency. COVID-19 can be asymptomatic or mild in most cases, but it
can rapidly progress to a severe lung inflammation leading to Acute Respiratory Distress
Syndrome (ARDS), especially for older adults (> 80 years) and/or with comorbidities (i.e.,
serious heart conditions, chronic pulmonary disease, diabetes mellitus, or hypertension
among others) [1‚Äì3]. The disease outcome mainly depends on the characteristics of the
viral replication and host immune responses, which can end up resolving the infection
efficiently or creating an exacerbated inflammation associated with severe lung damage
pathology, organ failure and poor outcomes [4,5].
The comprehensive long-term kinetics of SARS-CoV-2 RNA levels, anti-SARSCoV-2 antibodies (i.e., IgA, IgM, and IgG) and specific pro-inflammatory cytokines during
and after COVID-19 is not fully characterized, and it is of great interest for the
identification of early predictive biomarkers of severe disease and to understand the
clinical outcomes of patients after the remission of acute symptoms.
This study comprises an evaluation of clinical, virological and immunological
responses in a well-characterized cohort of hospitalized COVID-19 patients with
mild/moderate and severe disease. We performed a close follow-up at different time
points from the time of diagnosis and up to 6 months after the confirmation of the SARSCoV-2 infection. Moreover, we were able to identify viral and host-immune biomarkers
associated with COVID-19 severity. A delay in the SARS-CoV-2-RNA clearance in the
upper respiratory tract during the first days of the disease, higher concentrations of antiSARS-CoV-2 IgA, IgM, and IgG, and of specific cytokines (i.e., IL-6, IL-8 and MIP-1Œ≤) at
baseline were associated with COVID-19 severity. Overall, after 6 months, anti-SARSCoV-2 IgG persisted although at low levels.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

METHODS
Patients, sample collection and clinical data
The study population was selected from the COVID-19 Cohort of the Galicia Sur
Health Research Institute (COHVID-GS) (https://www.iisgaliciasur.es/apoyo -a-lainvestigacion/cohorte-covid19/). This cohort includes laboratory-confirmed SARS-CoV2 patients in clinical follow-up at the Vigo Healthcare Area with epidemiological/clinical
data and with a repository of biological samples (i.e., nasopharyngeal swabs, serum,
plasma and peripheral blood mononuclear cells-PBMCs) stored at the Galicia Sur Health
Research Institute Biobank. The epidemiological/clinical information was collected in a
Case Report Form (CRF) specifically predesigned for the COHVID-GS. The cohort also
includes a control group of uninfected individuals (anti-IgA, IgM and IgG SARS-CoV-2
negative). Written informed consent was obtained from each individual enrolled in the
COHVID-GS. All the techniques were performed in BLS-2 conditions, according to the
biosafety guidelines for handling and processing specimens associated with COVID-19
(https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html).
The selection criteria for this study were SARS-CoV-2 adult hospitalized patients
with a very close clinical follow-up with nasopharyngeal swabs, serum and plasma
samples, with consecutive samples available at least at baseline; and day 3 or 6; and
month 1 or 3 from their inclusion in the COHVID-GS. Moreover, only those patients
included in the COHVID-GS between day 1 and 5 following the confirmation of the
SARS-CoV-2 infection by RT-qPCR were considered. Serial paired nasopharyngeal
swabs, serum and plasma samples were collected from each patient at baseline, day 3
or 6, month 1 or 3 and at month 6. We also included 30 serum samples from healthy and
non-infected individuals as controls for the immunoassay experiments. Epidemiological
and clinical data were recorded for the study population.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Following WHO guidance, severe COVID-19 was defined as the need for invasive
mechanical ventilation, the development of Acute Respiratory Distress Syndrome
(PO2/FiO2 < 300 mmHg or Saturation O2/FiO2 < 330) or the admission to an Intensive
Care Unit (ICU) [6]. Patients who did not meet severe criteria were considered as
mild/moderate COVID-19.
SARS-CoV-2 RNA extraction
Viral RNA was extracted from 140 ¬µL of nasopharyngeal swab samples using the
QIAmp viral RNA mini kit (QIAGEN, Hilden, Germany) and the automatized QIAcube
system (QIAGEN, Hilden, Germany), and was eluted in 50 ¬µL of buffer following the
manufacturer‚Äôs instructions. The positive (SARS-CoV-2 Standard, EDx Exact
Diagnostics) and negative (SARS-CoV-2 Negative, EDx Exact Diagnostics) controls
were also extracted using the same procedure.

Droplet digital PCR analysis
SARS-CoV-2 viral load was quantified by reverse transcriptase droplet digital
PCR (RT-ddPCR), including the one-step reverse transcription (One-Step RT-ddPCR
Advanced Kit for Probes, Bio-Rad Laboratories) and the triplex probe assay for PCR
amplification (2019-nCoV CDC ddPCR Triplex Probe Assay, Bio-Rad Laboratories). The
assay contains primers and probes targeting two regions of the SARS-CoV-2
nucleocapsid gene (N1 and N2) and the human RNase P gene (RPP30). The reaction
mixture was performed with 5.5 ¬µL of SARS-CoV-2 RNA sample and following the
manufacturer‚Äôs instructions. All the samples were tested in duplicate. Data analysis was
performed using the QuantaSoft Analysis Pro Software (Bio-Rad Laboratories) which
showed the results as copies per microliter of 1x ddPCR reaction. All viral load values
were recalculated to copies per millilitre of swab, and the sensitivity threshold was 100
copies/mL. To assess the accuracy of the absolute viral RNA quantification, two-fold
serial dilutions of the positive control were analysed for lineal regression analysis. Finally,

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

to establish a reliable comparison between the viral load of different samples, the
absolute quantification of SARS-CoV-2 RNA was normalized with RPP30 and expressed
as copies/104 cells (supplementary material section).

Anti-SARS-CoV-2 IgA, IgG, and IgM quantification
The wells of 96-well immunoassay plates were coated overnight at 4¬∫C with 50
ŒºL of 5 Œºg/mL of SARS-CoV-2 nucleoprotein (NP) in 50 mM carbonate buffer pH 9.4.
The wells were washed three times with 200 ŒºL of PBS containing 0.05 % (v/v) Tween20 (PBST) and then blocked with 200 ŒºL of 5 % (w/v) skim milk in PBST for 30 min. After
another washing step, 50 ŒºL of serum samples (diluted 1/100 with PBS after heating for
30 min at 56¬∫C to inactivate residual virus) were added to the wells and incubated for 1
h. The wells were washed again three times with PBST and 50 ŒºL of anti-human IgAHRP, anti-human IgM-HRP or anti-human IgG-HRP enzyme conjugates diluted 1/20000
with PBST were added. After a final incubation for 30 min, the wells were washed five
times with PBST and 50 ŒºL of TMB Super Sensitive ELISA substrate were added in each
well. The reaction was stopped by the addition of 50 ŒºL of 1 M H2SO4 after 5 min for IgM
and IgA detection or 7 min for IgG detection. The absorbance at 450 nm was finally read
on a SPECTRAmax 340PC-384 microplate reader. The levels of IgA, IgM and IgG
antibodies in each sample were estimated using standard antibody calibration curves
performed in parallel in each plate as detailed in the supplementary information. Prepandemic serum samples were used as controls to set the background levels of the inhouse developed ELISA. All incubation steps were performed at room temperature (2225¬∫C) unless stated otherwise.

Plasma cytokines quantification
Plasma cytokines concentrations were determined using enzyme-linked
immunosorbent assays. Interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin 1 beta (IL1Œ≤), Tumor Necrosis Factor-alpha (TNF-Œ±), interferon-gamma (IFN-Œ≥), Macrophage

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Inflammatory Proteins 1 alpha (MIP-1Œ±) and 1 beta (MIP-1Œ≤) were analysed using a
multiplex bead-based immunoassay (MILLIPLEX¬Æ MAP Human High Sensitivity T Cell
Magnetic Bead Panel). Interferon gamma-induced protein 10 (IP-10), (Human CXCL10
ELISA kit, Abcam, Cambridge, UK) and soluble receptor interleukin 2 (sCD25) were
analysed using the Human Quantikine Immunoassay (R&D Systems). All following the
manufacturer‚Äôs instructions.

Statistics
The descriptive analyses were reported as frequencies and percentages for
categorical variables and medians and interquartile ranges (IQRs) for continuous
variables. To compare antibody levels between COVID-19 patients and a peer control
group, and to compare SARS-CoV-2 viral load and cytokines between severe and
mild/moderate patients, Mann-Whitney U test was performed. To assess the differences
in the viral load overtime and the concentration of the cytokines in several time points
during the first 6 months after SARS-COV-2 infection, a Wilcoxon Signed Rank test was
performed. Finally, Mann-Whitney U test was also used to compare the baseline
antibodies levels and baseline cytokines concentration with the severe clinical outcomes
(ICU admission, requirement of invasive mechanical ventilation and development of
Acute Respiratory Distress Syndrome). Statistical analyses were done with SPSS
version 19 and GraphPad Prism 8.2.1 and a p value less than 0.05 was considered
statistical significance.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

RESULTS
Demographic and clinical characteristics of the studied patients
A total of 24 hospitalized laboratory-confirmed COVID-19 patients were included
in the study. The demographic and most relevant clinical characteristics related with
COVID-19 are shown in Table 1. Most 83% (20/24) were males with a median age of 61
years old (IQR: 48-75.3). Nearly 50% (12/24) of patients met obese criteria (BMI ‚â• 30)
and 42% (10/24) had hypertension. The median hospitalization time was 8 days, and
21% (5/24) were admitted to the ICU. Eight of them (33.3%) met criteria for severe
COVID-19 disease.

SARS-CoV-2 viral load kinetics
The SARS-CoV-2 viral load quantification was performed from 92 RNA samples
extracted from nasopharyngeal swabs in the 24 patients at different time-points (24 at
baseline, 18 at day 3, 13 at day 6, 5 at day 15, 16 at month 1, and 16 at month 3) (Table
2). At baseline, 23 of 24 patients (96%) were positive for SARS-CoV-2 with a median
viral load of 2227.17 copies/104 cells showing broad variability between patients (IQR:
69.78 ‚Äì 7.42x104). Only one patient was negative for SARS-CoV-2 RNA quantification
but with low amplification of RPP30 indicating a deficient sampling. Overall, SARS-CoV2 viral load decrease overtime, and most of the patients (80%) were negative one month
after the diagnosis (Figure 1A). However, 5 patients showed persistent viral load at
month 1 and 3. All these patients had severe disease (COV 006, COV 009 and COV
013) and/or comorbidities such as diabetes (COV 016 and COV 013); hypertension or
cardiovascular disorders (COV 016, COV 019 and COV 013); chronic lung disease and
HIV infection (COV 009) and dyslipidemia (COV 006). Two different profiles in SARSCoV-2 kinetics were observed during acute infection based on the COVID-19 clinical
outcomes. A delay for the significant decline of SARS-CoV-2 levels during the first 6 days
of follow-up was recognized for those patients with severe disease. Thus, while for
patients with mild/moderate disease a significant decline in viral load is observed since

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

the diagnosis time, for patients with severe disease is only observed after day 6 (Figure
1B).

Anti-SARS-CoV-2 antibodies kinetics
The anti-SARS-CoV-2 antibodies levels were quantified at different time-points
from a total of 109 serum samples (24 at baseline, 18 at day 3, 13 at day 6, 5 at day 15,
16 at month 1, 18 at month 3 and 15 at month 6) (Figure 2). Overall, a high variability in
the IgA baseline levels was observed among patients that progressively increase
reaching the highest median levels at day 6 of follow-up, and then, significantly decrease
until month 6 (p= 0.028). The highest levels of IgA at baseline and during the follow-up
were observed for patients with severe COVID-19 (COV 006, COV 008, COV 010, COV
014, COV 013) (Figure 2A). A similar pattern was observed for the kinetics of IgM with
an on-going increase reaching the maximum levels at day 6 with a significant decline
after that (p=0.028). Likewise to IgA, the highest levels of IgM at baseline and during the
follow-up were observed for patients with severe COVID-19 (COV 008, COV 011, COV
010, COV 020) (Figure 2B). For IgG there was also a gradual increase until day 6 with
a progressive but slowly decrease until month 6 reaching very low concentrations
(Figure 2C). Of note, IgG levels at month 6 were significantly higher than for a group of
30 uninfected controls (15.93 vs. 4.50 Œºg/mL, respectively p-value < 0.001) (Figure 2D).
The numerical data for IgA, IgM and IgG in serum during the study period are
shown as supplementary data (Supplementary Table 1).

Plasma cytokines kinetics
Plasma cytokines levels were performed in a total of 18 patients, 12 with
mild/moderate and 6 with severe COVID-19, at different time-points (18 at baseline, 15
at month 1, 14 at month 3, and 17 at month 6). Figure 3 shows the dynamic of the
median concentrations of the 9 cytokines assessed (TNF-ùõº, IL-6, IL-8, IL-1Œ≤, MIP-1ùõº,

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

MIP-1Œ≤, IFN-ùõæ, sCD25 and IP-10) for each group based on COVID-19 severity during
the study period.
At baseline, significant higher levels of IL-6, IL-8, and MIP-1Œ≤ were observed for
patients with severe disease compared with those with mild/moderate COVID-19.
Overall, a similar dynamic was observed for some of the pro-inflammatory markers, IL6, IL-8, IP-10, TNF-ùõº and sCD25 during the study period. By contrast, the dynamic for
MIP-1Œ≤, IL-1Œ≤, MIP-1ùõº and IFN-ùõæ showed a different profile during the follow-up with
significant higher levels at month 1 (IL-1Œ≤ and IFN-ùõæ) and month 3 (MIP-1Œ≤, IL-1Œ≤, MIP1ùõº and IFN-ùõæ) among patients with mild/moderate diseases compared to those with
severe COVID-19. After 6 months of the acute SARS-COV-2 infection no differences
were found between patients with mild/moderate vs. severe disease.
The numerical data for plasma cytokines comparison between mild/moderate vs.
severe patients are shown as supplementary data (Supplementary Table 2).
Clinical, virological and host immune biomarkers for severe COVID-19 outcomes
A univariate analysis was performed to identify potential biomarkers associated
with severe clinical outcomes, defined as the requirement of invasive mechanical
ventilation, the admission to an Intensive Care Unit (ICU) and the development of Acute
Respiratory Distress Syndrome (ARDS). Higher levels of IgA, IgM, IgG against SARSCoV-2 and also the cytokines IL-6, IL-8 and MIP-1Œ≤ at baseline was observed among
patients who developed ARDS compared to those without ARDS. Moreover, higher
levels of IL-6 and MIP-1Œ≤ were related with either the need of invasive mechanical
ventilation or ICU admission. Overall, SARS-CoV-2 viral load at baseline was not
associated with any of the severe clinical outcome definitions (Table 3).

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

DISCUSSION
In this study we report that elevated levels of anti-SARS-CoV-2 antibodies, IgA,
IgM, and IgG as well as specific cytokines such as IL-6, IL-8, MIP-1Œ≤ during SARS-CoV2 acute infection are associated with severe COVID-19, defined by the development of
ARDS or the need of invasive mechanical ventilation or UCI admission. IgG persists after
6 months of the diagnosis but at lower concentrations. Whilst the levels of some
cytokines (i.e., IL-6, IL-8, IP-10, TNF-ùõº, sCD25) decline one month after of SARS-CoV2 diagnosis, others (MIP-1Œ≤, IL-1Œ≤, MIP-1ùõº and IFN-ùõæ) showed higher levels at month 1
and/or 3 for patients with mild/moderate disease compared to those with severe COVID19. However, after 6 months after diagnosis, no differences in cytokines levels between
patients with mild/moderate vs. severe disease were observed. Interestingly, although
SARS-CoV-2 RNA levels were not associated with the clinical outcome, during the acute
infection, a significant delay in SARS-CoV-2 viral load decline was recognized for
patients with severe COVID-19 as compared to those with mild/moderate COVID-19
during the first 6 days of follow-up.
Overall, SARS-CoV-2 viral load kinetics follows the pattern described previously,
reaching maximum levels during acute infection and decreasing progressively until
becoming undetectable in most patients in less than one month following diagnosis [7‚Äì
10]. However, because of the close follow-up of these patients we were able to identify
a significant delay during the first days of viral load decay for patients who met the criteria
for severe COVID-19. Nonetheless, in our cohort, SARS-CoV-2 RNA levels were not
associated with the clinical outcome at any time point. There are some controversial data
regarding this issue, while some studies have not reported any association between
SARS-CoV-2 viral load during acute infection and COVID-19 severity [11,12] others point
out that elevated viral load could be used to identify patients at higher risk for morbidity
or severe COVID-19 outcome [13,14]. The controversial results might be explained for
the heterogeneity of the studies related to the different characteristics of the study

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

population and/or the methodology used for SARS-CoV-2 quantification and sampling
quality (i.e., normalization using copies/cells).
Although, 80% of patients showed undetectable viremia one month after the
diagnosis, in 5 patients we observed SARS-CoV-2 RNA persistence between month 1
and 3. Interestingly, all of these had severe disease and/or comorbidities (i.e., diabetes,
hypertension or cardiovascular disorders, chronic lung disease and HIV infection,
dyslipidemia). These observations are in agreement with previous studies that reported
an association between SARS-CoV-2 RNA persistence with severe disease [9,15] and
comorbidity [13,16‚Äì18] following remission of the acute symptoms. More recently,
Jacobs et al., highlighted the association between SARS-CoV-2 plasma viremia with ICU
admission [19] and Tokuyama et al., described SARS-CoV-2 persistence in intestinal
enterocytes up to 7 months after symptoms resolutions [20]. Additional studies are
required to better understand the clinical significance of SARS-CoV-2 persistence in
different compartments (i.e., plasma, gut, upper respiratory tract) and its potential use to
monitor COVID-19 patients during the early acute infection and/or following the remission
of the acute symptoms.
We found that elevated levels of anti-SARS-CoV-2 antibodies during acute
infection are related with severe COVID-19. Those patients who developed ARDS
showed significantly higher levels of IgA, IgM, and IgG, compared to patients without
ARDS. These findings are in agreement with previous studies that found an association
between anti-SARS-CoV-2 antibodies levels and the need for intubation or death
[21,22]. Overall, we observed that anti-SARS-CoV-2 IgA and IgM antibodies decay
rapidly after the acute infection phase (i.e., at month 3, 54% for IgA and 77% for IgM
showed levels below the limit of detection) but the decline for IgG was less prominent
and persisted until month 6. These levels were still significantly higher compared to the
levels of uninfected controls (15.93 vs. 4.50 Œºg/mL, respectively p-value < 0.001). The
durability of the immune responses against SARS-CoV-2 infection is a matter of intense

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

interest and still remains unclear. Regarding the humoral responses, recent studies have
also reported that IgG levels persist between 6 and 8 months after onset of symptoms
[23,24]. However, plasma neutralization activity seems to decrease a few weeks after
the onset of the symptoms [25]. Understanding the dynamics of antibodies against
SARS-CoV-2 and the persistence of the neutralizing activity is critical to establish correct
prevention and vaccination strategies.
COVID-19 severity has been associated with an exacerbated inflammation due
to a massive release of pro-inflammatory components [4,5]. We have identified that
elevated levels of IL-6, IL-8, MIP-1Œ≤ during SARS-CoV-2 acute infection are associated
with severe COVID-19 defined by the development of ARDS or the need of invasive
mechanical ventilation or UCI admission. Higher levels of IL-6 have been consistently
related with severe COVID-19 disease [26,27] and play a pivotal role in the cytokine
storm in response to SARS-CoV-2 infection promoting organ failure and severe lung
pathology [28‚Äì30]. IL-8 leads the activation and the recruitment of neutrophils to the
inflammation sites and has been implicated in inflammatory pulmonary diseases such as
ARDS, chronic obstructive pulmonary disease, and asthma [31,32]. MIP-1Œ≤ drives the
recruitment of a variety of innate and adaptive immune cells and high concentrations
have been reported in the serum and lungs of patients with certain acute respiratory viral
infections [33,34]. However, their role during SARS-CoV-2 infection remains unclear.
Some studies have reported a higher production of MIP-1Œ≤ at the transcriptional level in
bronchoalveolar lavage cells isolated from the lungs of severe COVID-19 patients
[35,36], whilst other studies did not find an association between MIP-1Œ≤ and severe
disease [28,37].
The levels of IL-6, IL-8, and MIP-1Œ≤ significantly decline at month 1 showing
similar levels during the follow-up to those patients with mild/moderate disease. Overall,
a similar dynamic was observed for IP-10, TNF-ùõº and sCD25 during the study period.
By contrast, the dynamic for MIP-1Œ≤, IL-1Œ≤, MIP-1ùõº and IFN-ùõæ showed a different

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

evolution pattern with a significant increase at month 1 and/or 3 among patients with
mild/moderate disease compared to those with severe COVID-19. No differences were
observed in the levels of these cytokines 6 months after of the acute SARS-COV-2
infection between patients with mild/moderate vs. severe disease. Therefore, the
unbalance in the cytokine levels between severe and mild/moderate COVID-19 patients
seems to be restored after 6 months of SARS-CoV-2 infection. A previous study by Lucas
et al., [38] also reported no differences at the IL-6, IL-8 and IP-10 levels between
mild/moderate and severe outcomes after 20 days of follow-up.
This study presents some limitations. First, the relatively small size of the study
population mainly represented by men as during the first wave of COVID-19 in our
institution 86% of hospitalized patients were men. However, we were able to accomplish
a very close follow-up of the clinical outcomes, viral and host immune factors in this
population allowing interesting observations. Although we have identified IgG after 6
months of SARS-CoV-2 infection we did not assess their neutralization activity and
therefore the risk upon new SARS-CoV-2 re-infections. External validation should be
assessed to confirm the predictive value of our findings.
In conclusion, in a well-characterized cohort of hospitalized COVID-19 with
mild/moderate and severe disease and close clinical follow-up during and after 6 months
of SARS-CoV-2 infection we have recognized early host immune predictors of severity.
Higher levels of IgA, IgM, and IgG and the specific cytokines IL-6, IL-8, and MIP-1Œ≤
during acute infection were observed in those patients with a severe COVID-19 outcome.
Conversely, higher levels of IL-1Œ≤ and IFN-ùõæ and at month 1 and MIP-1Œ≤, IL-1Œ≤, MIP-1ùõº
and IFN-ùõæ month 3 were observed among patients with mild/moderate diseases
compared to those with severe COVID-19. IgG against SARS-CoV-2 persisted after 6
months of the diagnosis.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Acknowledgments
We would like to thank all the members of COHVID-GS and IISGS Biobank, patients,
nursing staff and Celta Ingenieros (A Coru√±a, Spain) for their kind supply of ddPCR
reagents.
Sources of financial support:
This

work

was

supported

by

Plan

Estatal

de

I+D+I

2013-2016

and

2017-2020 and cofinanced by Instituto de Salud Carlos III (ISCIII) - Subdirecci√≥n General
de Evaluaci√≥n y Fomento de la investigaci√≥n del Fondo Europeo de Desarrollo Regional
(FEDER), Fondo COVID19 of Instituto de Salud Carlos III (COV20/00698), RETICS, Red
de Investigaci√≥n en SIDA [RD16/0025/0026]; and Fundaci√≥n Biom√©dica Galicia Sur.
E.R-M. was supported by Spanish Research Council (CSIC) and by the research grant
CV20-85418

from

the

Consejer√≠a

de

Transformaci√≥n

Econ√≥mica,

Industria,

Conocimiento y Universidades (Junta de Andaluc√≠a). A.G-V was supported by the
Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund
(‚ÄúA way to achieve Europe‚Äù), Subprograma Miguel Servet (CP19/00159). E.M.M. was
supported by the Instituto de Salud Carlos III, cofinanced by the European Development
Regional Fund (‚ÄúA way to achieve Europe‚Äù), Subprogram PFIS (FI19/00304). C.K was
supported by Fondo COVID19 of Instituto de Salud Carlos III (COV20/00823).

Declaration of interests
The authors declare no competing interests.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

REFERENCES

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020; 395: 507-513.
2. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute
respiratory distress syndrome. Lancet Respir Med. 2020; 8:420-422.
3. Hu J, Wang Y. The Clinical Characteristics and Risk Factors of Severe COVID-19.
Gerontology. 2021; Jan 6:1‚Äì12.
4. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With
Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71:762-768.
5. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‚Äô in
COVID-19. J Infect. 2020; 80:607-613.
6. World Health Organization. COVID-19 Clinical management: living guidance. World
Health Organization 2021. Available from:
https://www.who.int/publications/i/item/WHO- 2019-nCoV-clinical-2021-1
7. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity
over the course of an infection. J Infect. 2020; 81:357‚Äì371.
8. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility
of COVID-19. Nat Med. 2020; 26:672-675.
9. N√©ant N, Lingas G, Le Hingrat Q, et al. Modeling SARS-CoV-2 viral kinetics and
association with mortality in hospitalized patients from the French COVID cohort.
Proc Natl Acad Sci U S A. 2021; 118:e2017962118.
10. Alteri C, Cento V, Antonello M, et al. Detection and quantification of SARS-CoV-2 by
droplet digital PCR in real-time PCR negative nasopharyngeal swabs from
suspected COVID-19 patients. PLoS One. 2020; 15:e0236311.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

11. Argyropoulos K v., Serrano A, Hu J, et al. Association of Initial Viral Load in Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome
and Symptoms. Am J Pathol. 2020; 190:1881-1887.
12. Le Borgne P, Solis M, Severac F, et al. SARS-CoV-2 viral load in nasopharyngeal
swabs in the emergency department does not predict COVID-19 severity and
mortality. Acad Emerg Med. 2021; 28:306-313.
13. Komissarov A, Molodtsov I, Ivanova O, et al. High SARS-CoV-2 load in the
nasopharynx of patients with a mild form of COVID-19 is associated with clinical
deterioration regardless of the hydroxychloroquine administration. PLoS One. 2021;
16:e0246396.
14. Maltezou HC, Raftopoulos V, Vorou R, et al. Association Between Upper Respiratory
Tract Viral Load, Comorbidities, Disease Severity, and Outcome of Patients With
SARS-CoV-2 Infection. J Infect Dis. 2021; 223:1132-1138.
15. Lescure F-X, Bouadma L, Nguyen D, et al. Clinical and virological data of the first
cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020; 20:697-706.
16. Buetti N, Trimboli P, Mazzuchelli T, et al. Diabetes mellitus is a risk factor for
prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically
ill patients. Endocrine. 2020; 70:454-460.
17. Fu Y, Han P, Zhu R, et al. Risk factors for viral RNA shedding in COVID-19 patients
Eur Respir J. 2020; 56:2001190.
18. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia Increases the Risk of Severe
COVID-19: A Systematic Review, Meta-analysis, and Meta-regression. J Clin Exp
Hepatol. 2021; Feb 8.
19. Jacobs JL, Staines B, Bain W, et al. COVID-19 outcome: insights from quantification
of viremia and neutralizing antibody [abstract 116]. In: Abstracts From the virtual
CROI 2021 Conference on Retroviruses and Opportunistic Infections. 2021.
20. Tokuyama M, Ladinsky MS, Jha D, et al. SARS-COV-2 persists in intestinal
enterocytes up to 7 months after symptom resolution [abstract 115]. In: Abstracts

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

From the virtual CROI 2021 Conference on Retroviruses and Opportunistic
Infections. 2021.
21. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies
predict disease severity and survival. Cell. 2021; 184:476-488.
22. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients
with COVID-19. Nat Med. 2020; 26:845-848.
23. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed
for up to 8 months after infection. Science. 2021; 371:eabf4063.
24. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARSCoV-2. Nature. 2021; 591:639-644.
25. Beaudoin-Bussi√®res G, Laumaea A, Anand SP, et al. Decline of Humoral Responses
against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020; 11:e0259020.
26. Santa Cruz A, Mendes-Frias A, Oliveira AI, et al. Interleukin-6 Is a Biomarker for the
Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2
Pneumonia. Front Immunol. 2021; 12:613422.
27. Valle DM del, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature
predicts COVID-19 severity and survival. Nat Med. 2020; 26:1636-1643.
28. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet. 2020; 395:497-506.
29. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and
moderate coronavirus disease 2019. J Clin Invest. 2020; 130:2620-2629.
30. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host Response to
SARS-CoV-2 Drives Development of COVID-19. Cell. 2020; 18:1036-1045.e9.
31. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and
cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
EBioMedicine. 2020; 55:102763.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

32. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases.
Am J Physiol Lung Cell Mol Physiol. 2003; 284:L566-77.
33. Melchjorsen J, S√∏rensen LN, Paludan SR. Expression and function of chemokines
during viral infections: from molecular mechanisms to in vivo function. J Leukoc Biol.
2003; 74:331-43.
34. Nuriev R, Johansson C. Chemokine regulation of inflammation during respiratory
syncytial virus infection. F1000Research. 2019; 8:F1000 Faculty Rev-1837.
35. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells
in patients with COVID-19. Nat Med. 2020; 26:842-844.
36. Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza
highlights the role of type I interferons in development of severe COVID-19. Sci
Immunol. 2020; 5:eabd1554.
37. Chi Y, Ge Y, Wu B, et al. Serum Cytokine and Chemokine Profile in Relation to the
Severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020; 222:746-754.
38. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring
in severe COVID-19. Nature. 2020; 584:463-469.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

FIGURES AND TABLES
Table 1. Demographic and clinical characteristics of the study population.

Characteristics

n=24

Age (years)

61.0 (48.0 ‚Äì 75.3)

Sex (male)

83% (20)

Comorbidities
Obesity BMI>30

50% (12)

Hypertension

42% (10)

Chronic lung disease

21% (5)

Dyslipidemia

21% (5)

Cardiovascular disease

13% (3)

Diabetes

13% (3)

Hospitalization time (days)
ICU admission
ICU length of stay (days)
Exitus

8.0 (7.0 ‚Äì 16.3)
21% (5)
12.0 (9.0 ‚Äì 18.5)
4% (1)

Time from symptom onset to hospital admission (days)

9.0 (5.5 ‚Äì 13.0)

Time from hospital admission to cohort admission (days)

2.0 (2.0 ‚Äì 3.0)

Time from PCR+ to cohort admission (days)

3.0 (2.0 ‚Äì 5.0)

Symptoms on admission
Fever

75% (18)

Dyspnea

71% (17)

Cough

67% (16)

Malaise

67% (16)

Diarrhea

42% (10)

Sputum

38% (9)

ARDS*

30% (7)

Myalgia/Arthralgia

30% (7)

Anosmia

25% (6)

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Chest pain

25% (6)

Median laboratory values on admission
Leukocytes (cells/mL)
Lymphocytes (cells/mL)
Neutrophils (cells/mL)

4940.0 (4545.0 ‚Äì 6815.0)
955.0 (755.0 ‚Äì 1215.0)
3725.0 (2860.0 ‚Äì 5437.5)

Platelets (x109/L)

166.5 (132.8 ‚Äì 248.0)

Creatinine (mg/dL)

0.885 (0.778 ‚Äì 1.023)

LDH (UI/L) **

274.0 (208.0 ‚Äì 350.0)

Bilirubin (mg/dL)**

0.660 (0.430 ‚Äì 0.900)

Oxygen therapy

58% (14)

Invasive mechanical ventilation

21% (5)

Pulmonary infiltrates

92% (22)

Treatments during hospitalization
Hydroxychloroquine

71% (17)

Antibiotics

46% (11)

Immunosuppressive therapy

46% (11)

Corticosteroids

42% (10)

Lopinavir/Ritonavir

42% (10)

Azithromycin

30% (7)

Data are median (IQR), % (n).
*Acute Respiratory Distress Syndrome.
** n=23

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Table 2. SARS-CoV-2 RNA quantification from nasopharyngeal swab samples.

SARS-CoV-2 RNA (copies/104cel*)
Case

Baseline

Day 3

Day 6

Day 15

Month 1

Month 3

COV 001

1.03x104

4.70x105

202.55

NA

ND

NA

COV 002

3.73x106

3.48x103

NA

NA

ND

ND

COV 003

42.52

25.75

NA

NA

ND

ND

COV 004

3.27x103

171.77

NA

NA

ND

ND

COV 005

107.84

ND

NA

NA

ND

ND

COV 006

71.27

NA

228.31

ND

NA

76

COV 007

116.38

43.68

NA

NA

ND

ND

COV 008

5.43x104

1.10x104

21.24

NA

ND

ND

COV 009

7.08x104

424.73

9.97

13.67

NA

52.8

COV 010

69.28

307.3

NA

NA

ND

ND

COV 011

1.19x103

NA

1.65x103

ND

ND

ND

COV 012

4.75x105

NA

1.10x104

ND

NA

NA

COV 013

1.53x105

9.81x105

195.8

NA

408.3

NA

COV 014

35.74

10.16

ND

NA

ND

ND

COV 015

ND

ND

NA

NA

ND

ND

COV 016

7.54x104

5.91x104

NA

NA

45.43

7.68

COV 017

59.94

NA

ND

NA

ND

ND

COV 018

5.89

ND

NA

NA

ND

ND

COV 019

6.88x104

1.42x103

NA

NA

NA

251.4

COV 020

946.4

53.6

81.3

25.2

ND

NA

COV 021

400

169.51

ND

NA

NA

NA

COV 022

3.09x105

NA

202.8

NA

NA

NA

COV 023

2.56x106

2.37x105

NA

NA

NA

NA

COV 024

4.42x103

NA

11.1

NA

NA

NA

*copies/104cel: number of viral RNA copies per 104 cells. ND: not detected. NA: sample not
collected. Patients from the COVID-19 severe group are highlighted in bold.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 1.

A

Viral load

SARS-CoV-2 viral load
(Log10 copies/104 cells)

7
6
5
4
3
2
1
0

0

3

6

30

60

90

Follow-up (days)

Viral load

B

SARS-CoV-2 viral load
(Log10 copies/104 cells)

6

p=0.345

p=0.063

p=0.026

p=0.028

Mild/Moderate
Severe

5
p=0.028

4
p=0.008
p=0.046

3

p=0.008

2
1
0

0

3

6

30

Follow-up (days)

60

90

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 2.

A

IgA

IgA
150

150

100

100

ùõçg/mL

ùõçg/mL

COV 008
COV 010

COV 013

0

B

D3

D6

M1

M3

0

M6

B

D3

D6

10

20

8

15

6

10
5
0

D15

M1

M3

M6

IgM

IgM
25

ùõçg/mL

ùõçg/mL

COV 014

50

50

B

COV 006

COV 008
COV 010

COV 011

4

COV 020

2

B

D3

D6

C

M1

M3

0

M6

B

D3

D6

IgG

D15

M1

M3

M6

IgG
1000
800

ùõçg/mL

ùõçg/mL

400

200

COV 006

600

COV 009

400
200

0

D

B

D3

D6

M1

M3

IgG
80
‚ú±‚ú±‚ú±

ùõçg/mL

60

40

20

0

C

M6

M6

0

B

D3

D6

D15

M1

M3

M6

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 3.

IL-6
120

IP-10

IL-8
50

**

80

5000

**

40

4000

30

3000

20

40

2000

10

1000

0

0

0

30

60

90

120 150 180

0

0

30

60

90

[Cytokine] (pg/mL)

0

120 150 180

30

60

90

120 150 180

MIP-1Œ≤

sCD25

TNF-Œ±

40

4000

20

Mild/Moderate
Severe

**
3000

10

*

20

2000
1000

0

0

0
0

30

60

90

0

120 150 180

30

60

IL-1Œ≤
5

90

120 150 180

0

30

60

90

120 150 180

IFN-Œ≥

MIP-1Œ±
60

150

40

100

4
3

*
*

2

**

20

1
0

0
0

30

60

90

120 150 180

*

*

50

0

0

30

60

90

120 150 180

Follow-up (days)

0

30

60

90

120 150 180

84.94 (57.32 - 102.03)

0.66 (0.59 - 6.25)

IgG

IgM

0.083

8.12 (7.32 - 11.56)

11.55 (10.40 - 17.45)

TNF-ùõº

0.750

1.50 (1.31 - 2.02)
12.74 (7.95 - 15.47)
35.91 (26.79 - 53.89)

1.65 (1.07 - 1.77)

18.52 (5.02 - 24.21)

47.59 (36.60 - 101.63)

IL-1Œ≤

MIP-1ùõº

IFN-ùõæ

42.13 (40.57 - 77.18)

15.11 (10.87 - 18.52)

37.01 (30.6 - 53.66)

13.36 (8.34 - 19.62)

1.60 (1.30 - 1.80)

16.60 (9.98 - 19.99)

30.82 (24.47 - 37.55)
1.62 (1.42 - 1.73)

1465.00 (960.95-2534.50)

10.81 (7.55 - 11.73)

534.70 (177.65 - 614.15)

7.69 (5.02 - 10.88)

5.80 (3.72 - 16.57)

57.32 (6.47 - 281.21)

0.59 (0.17 - 4.96)

7.25 (1.22 - 50.07)

1567.00 (1515.00 - 2247.50)

10.96 (10.60 - 11.92)

1606.00 (1076.40 -3347.00)

21.56 (15.78 - 51.42)

38.51 (32.72 - 172.42)

17.42 (8.96 - 86.86)

0.56 (0.10 - 1.30)

6.18 (0 - 16.63)

3.51 (1.71- 4.88)

No ICU admission

ICU admission
3.07 (2.70- 5.01)

No invasive mechanical ventilation/

Invasive mechanical ventilation/

Data are median (IQR)
Mann-Whitney U test was performed. P-values < 0.05 were considered significant and are highlighted in bold.
a. ARDS n=7; No ARDS n=17; ICU admission n=5; No ICU admission n=19
b. ARDS n=6; No ARDS n=12; ICU admission n=3; No ICU admission n=15

0.213

0.682

0.001

15.37 (8.99 - 17.51)

25.29 (19.52 - 34.19)

MIP-1Œ≤

0.250

0.102

515.40 (141.3 - 633.13)

1083.80 (439.15 - 4613.25)

IP-10

2160.00 (1541.25 - 2877.0) 1221.50 (775.33 - 2806.00)

0.007

6.43 (4.64 - 9.51)

19.99 (9.83 - 45.67)

IL-8

sCD25

0.002

0.047

0.43 (0.09 - 1.06)

5.44 (2.93 - 11.63)

0.028

14.47 (8.38 - 57.71)

32.72 (20.78 - 107.92)

0.013

0.357

p-value

4.42 (0.0 - 14.32)

3.64 (1.92 - 5.36)

No ARDS

IL-6

Plasma cytokinesb (pg/mL)

24.51 (7.25 - 75.62)

2.97 (1.78 - 4.73)

IgA

Serum antibodiesa (Œºg/mL)

(Log10 copies/104 cells)

SARS-CoV-2 viral load

ARDS

Table 3. Biomarkers of severe COVID-19.

0.301

1.000

1.000

0.039

0.645

0.574

0.100

0.056

0.017

0.836

0.446

0.783

0.804

p-value

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

FIGURE LEGENDS

Figure 1. SARS-CoV-2 viral load kinetics. A) SARS-CoV-2 RNA levels among study
period. B) Median SARS-CoV-2 RNA levels in patients with mild/moderate versus
severe COVID-19. A) SARS-CoV-2 RNA levels among the overall study population
during the study period. The black dots represent the aligned individual values obtained
from each time-point. The solid line represents the connected mean values. The dotted
line indicates the established experimental threshold (below the lowest positive sample
obtained in our study). B) Median ¬± IQR SARS-CoV-2 RNA levels in patients with
mild/moderate versus severe COVID-19. The solid line with black circles represents the
mild/moderate group and dotted line with black squares represents the severe group.
Wilcoxon Signed Rank Test was performed for the decline of viral load between timepoints; p: p-value.

Figure 2. Absolute levels at different time points during the study period and
antibodies IgA (A), IgM (B) and IgG (C) kinetics in specific patients. D) Comparison
of IgG levels between uninfected controls and patients after 6 months of SARSCoV-2 infection. Absolute levels of IgA (A), IgM (B) and IgG (C) among the overall study
population (n=24) at baseline (B), day 3 (D3), day 6 (D6), month 1 (M1), month 3 (M3)
and month (M6) after SARS-CoV-2 infection and changes of serum IgA (A), IgM (B) and
IgG (C) antibodies in specific patients (n=19) at baseline (B), day 3 (D3), day 6 (D6),
month 1 (M1), month 3 (M3) and month (M6) after SARS-CoV-2 infection. Patients COV
006, COV 008, COV 009, COV 010, COV 011, COV 013, COV 014 and COV 020 belong
to the severe group. D) Difference in IgG levels between uninfected controls (n=30) and
patients after 6 months of SARS-CoV-2 infection (n=15) was determined by MannWhitney U test. ***, p-value < 0.0001.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439586; this version posted April 13, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 3. Cytokine kinetics in patients with mild/moderate versus severe COVID19 during the study period. Cytokine levels are expressed as median ¬± IQR. The solid
line with black circles represents the mild/moderate group (n=12) and dotted line with
black squares represents severe group (n=6). Differences between both groups at each
time-point was assessed using Mann-Whitney U test. *, p-value < 0,05; **, p-value <
0.001.

